Relapse After Allogeneic Stem Cell Transplantation

Overview

Journal Expert Rev Hematol

Specialty Hematology

Date 2010 Nov 19

PMID 21083034

Citations 87

Authors

A John Barrett

Minoo Battiwalla

Affiliations

Soon will be listed here.

Abstract

Since allogeneic stem cell transplantation (SCT) represents an intensive curative treatment for high-risk malignancies, its failure to prevent relapse leaves few options for successful salvage treatment. While many patients have a high early mortality from relapse, some respond and have sustained remissions, and a minority has a second chance of cure with appropriate therapy. The prognosis for relapsed hematological malignancies after SCT depends on four factors: the time elapsed from SCT to relapse (with relapses occurring within 6 months having the worst prognosis), the disease type (with chronic leukemias and some lymphomas having a second possibility of cure with further treatment), the disease burden and site of relapse (with better treatment success if disease is treated early), and the conditions of the first transplant (with superior outcome for patients where there is an opportunity to increase either the alloimmune effect, the specificity of the antileukemia effect with targeted agents or the intensity of the conditioning in a second transplant). These features direct treatments toward either modified second transplants, chemotherapy, targeted antileukemia therapy, immunotherapy or palliative care.

Citing Articles

Age and dose dependent changes to the bone and bone marrow microenvironment after cytotoxic conditioning with busulfan.

Abbasizadeh N, Burns C, Verrinder R, Ghazali F, Seyedhassantehrani N, Spencer J Front Cell Dev Biol. 2024; 12:1441381.

PMID: 39139448 PMC: 11319712. DOI: 10.3389/fcell.2024.1441381.

Clinical impact of clonal hematopoiesis in hematopoietic cell transplantation: a review, meta-analysis, and call to action.

Gillis N, Ebied A, Thompson Z, Pidala J Haematologica. 2024; 109(12):3952-3964.

PMID: 38899345 PMC: 11609801. DOI: 10.3324/haematol.2024.285392.

A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ-induced CD38 expression.

Murtadha M, Park M, Zhu Y, Caserta E, Napolitano O, Tandoh T Blood. 2024; 143(16):1599-1615.

PMID: 38394668 PMC: 11103097. DOI: 10.1182/blood.2023021570.

Multiple imputation strategies for missing event times in a multi-state model analysis.

Curnow E, Hughes R, Birnie K, Tilling K, Crowther M Stat Med. 2024; 43(6):1238-1255.

PMID: 38258282 PMC: 7616776. DOI: 10.1002/sim.10011.

Editorial: 50 years of BMT: risk stratification, donor matching and stem cell collection for transplantation.

Hamerschlak N, Gomez-Almaguer D, McLornan D Front Oncol. 2024; 13:1321334.

PMID: 38169637 PMC: 10758429. DOI: 10.3389/fonc.2023.1321334.

References

Mielcarek M, Storer B, Flowers M, Storb R, Sandmaier B, Martin P . Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2007; 13(10):1160-8. DOI: 10.1016/j.bbmt.2007.06.007. View

Cutler C, Kim H, Hochberg E, Ho V, Alyea E, Lee S . Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2004; 10(5):328-36. DOI: 10.1016/j.bbmt.2003.12.305. View

Morris J, Waldmann T . Antibody-based therapy of leukaemia. Expert Rev Mol Med. 2009; 11:e29. PMC: 7294739. DOI: 10.1017/S1462399409001215. View

Al-Qurashi F, Ayas M, Al Sharif F, Ibrahim E, Sahovic E, Al Mahr M . Second allogeneic bone marrow transplantation after myeloablative conditioning analysis of 43 cases from single institution. Hematology. 2004; 9(2):123-9. DOI: 10.1080/10245330310001652509. View

Lu Y, Waller E . Dichotomous role of interferon-gamma in allogeneic bone marrow transplant. Biol Blood Marrow Transplant. 2009; 15(11):1347-53. PMC: 2782586. DOI: 10.1016/j.bbmt.2009.07.015. View

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

Barrett A, Joshi R, Tew C . How should acute lymphoblastic leukaemia relapsing after bone-marrow transplantation be treated?. Lancet. 1985; 1(8439):1188-91. DOI: 10.1016/s0140-6736(85)92865-x. View

Khong H, Restifo N . Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002; 3(11):999-1005. PMC: 1508168. DOI: 10.1038/ni1102-999. View

Tiribelli M, Sperotto A, Candoni A, Simeone E, Buttignol S, Fanin R . Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leuk Res. 2008; 33(1):174-7. DOI: 10.1016/j.leukres.2008.03.031. View

10.

Blair A, Goulden N, Libri N, Oakhill A, Pamphilon D . Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation. Blood Rev. 2005; 19(6):289-300. DOI: 10.1016/j.blre.2004.09.002. View

11.

Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L . HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997; 276(5319):1719-24. DOI: 10.1126/science.276.5319.1719. View

12.

Keil F, Haas O, Fritsch G, Kalhs P, Lechner K, Mannhalter C . Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood. 1997; 89(9):3113-7. View

13.

Bloor A, Thomson K, Chowdhry N, Verfuerth S, Ings S, Chakraverty R . High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2007; 14(1):50-8. DOI: 10.1016/j.bbmt.2007.04.013. View

14.

Villalobos I, Takahashi Y, Akatsuka Y, Muramatsu H, Nishio N, Hama A . Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation. Blood. 2010; 115(15):3158-61. DOI: 10.1182/blood-2009-11-254284. View

15.

Sramkova L, Muzikova K, Fronkova E, Krejci O, Sedlacek P, Formankova R . Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2006; 48(1):93-100. DOI: 10.1002/pbc.20794. View

16.

Raiola A, Van Lint M, Valbonesi M, Lamparelli T, Gualandi F, Occhini D . Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant. 2003; 31(8):687-93. DOI: 10.1038/sj.bmt.1703883. View

17.

Ford C, Asch J, Konopa K, Petersen F . CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2009; 45(2):403-4. DOI: 10.1038/bmt.2009.146. View

18.

Collins Jr R, Shpilberg O, Drobyski W, Porter D, Giralt S, Champlin R . Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997; 15(2):433-44. DOI: 10.1200/JCO.1997.15.2.433. View

19.

Khouri I, Lee M, Saliba R, Jun G, Fayad L, Younes A . Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol. 2003; 21(23):4407-12. DOI: 10.1200/JCO.2003.05.501. View

20.

Ravandi F, Kantarjian H, Cohen A, Davis M, OBrien S, Anderlini P . Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant. 2001; 27(12):1221-5. DOI: 10.1038/sj.bmt.1703028. View